$239.60

FREE
SHIPPING

100% MONEY
BACK GUARANTEE

ONLINE
SUPPORT 24/7

Available on backorder. No lead time available. Please request a quote.
Sku CI02381_25_G
Chem Impex
Get Bulk Quote

Product Information

Product Name
Na-Fmoc-Nw-(4-toluenesulfonyl)-L-arginine
Brand Name
Chem Impex
Product Number
02381
CAS
83792-47-6
Certificate of Analysis (COA)​
COA not found

General Information

PubChem CID
3010412
IUPAC Name
(2S)-5-amino-(4-methylphenyl)sulfonylaminomethylideneamino-2-(9H-fluoren-9-ylmethoxycarbonylamino)pentanoic acid
InChI Key
JRRARHJPRLAGNT-VWLOTQADSA-N
SMILES
CC1=CC=C(C=C1)S(=O)(=O)NC(=NCCCC@@H(C(=O)O)NC(=O)OCC2C3=CC=CC=C3C4=CC=CC=C24)N

Application

Na-Fmoc-Nw-(4-toluenesulfonyl)-L-arginine is widely utilized in research focused on:

Peptide Synthesis: This compound serves as a key building block in the synthesis of peptides, allowing researchers to create complex molecules for drug development and biological studies.

Drug Development: It plays a significant role in developing pharmaceuticals, particularly in designing inhibitors or modulators for various biological pathways, enhancing therapeutic efficacy.

Bioconjugation: The compound is used in bioconjugation processes, facilitating the attachment of biomolecules to drugs or imaging agents, which is crucial for targeted therapy and diagnostics.

Research in Cancer Therapeutics: Its unique properties make it valuable in cancer research, where it can be used to design targeted therapies that selectively attack cancer cells while sparing healthy tissue.

Protein Engineering: This chemical aids in protein engineering applications, allowing scientists to modify protein structures for improved stability and functionality in various biotechnological applications.

References Data Source From Pubchem

Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure–activity relationship studies

Publication Name: Bioorganic & Medicinal Chemistry Letters
Publication Date: 2005-03-01
DOI: 10.1016/j.bmcl.2004.12.068

The discovery, characterization and crystallographically determined binding mode of an FMOC-containing inhibitor of HIV-1 protease

Publication Name: Bioorganic & Medicinal Chemistry
Publication Date: 1997-07
DOI: 10.1016/s0968-0896(97)00078-3